Faculty Information - Seiko Sugiyama

Present specialized field

Journal

Presentation

（Last updated : 2025-12-12 13:08:08）

Seiko Sugiyama
Department Kawasaki Medical School Kawasaki Medical School, Department of Dermatology,

Position Assistant Professor

■ Present specialized field

Dermatology

■ Journal

1.	2025/06/09	Comparing immunopathogenesis of non-human immunodeficiency virus immune reconstitution inflammatory syndrome and immune-related adverse events: A prospective multicenter cohort study
2.	2025/06/01	Differences in the management of toxic epidermal necrolysis related and unrelated to immune checkpoint inhibitors
3.	2025/05/29	Comparing immunopathogenesis of non-human immunodeficiency virus immune reconstitution inflammatory syndrome and immune-related adverse events: A prospective multicenter cohort study.
4.	2023/09/11	Biomarkers for predicting immune reconstitution inflammatory syndrome in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: A retrospective observational study with a case series
5.	2023/05/14	Positron emission tomography and computed tomography imaging in primary cutaneous nocardiosis with osteomyelitis clinically mimicking soft tissue sarcoma
6.	2023/04/17	Dramatic deterioration or new-onset dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid after COVID-19 vaccination: A possible manifestation of immune reconstitution inflammatory syndrome
7.	2022/07	Clinical features of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in Japan: A nationwide retrospective observational study.
8.	2022/06	Anti-Cytomegalovirus Therapy: Whether and When to Initiate, Those Are the Questions
9.	2022/06	Neutrophil to lymphocyte ratio is predictive of severe complications and mortality in patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: A retrospective longitudinal observational study
10.	2022/03/03	Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
11.	2022/02/27	Drug allergy and non-HIV immune reconstitution inflammatory syndrome
12.	2021/01/13	Risk factors for cytomegalovirus reactivation in autoimmune bullous disease patients on immunosuppressive therapy
13.	2020/08/13	Systemic capillary leak syndrome triggered by anti-programmed death 1 checkpoint inhibitor in psoriasis.
14.	2020/06/11	Acquired Haemophilia A in DPP4 Inhibitor-induced Bullous Pemphigoid as Immune Reconstitution Syndrome.
15.	2019/09	Prurigo nodularis as a sweat gland/duct-related disorder: resolution associated with restoration of sweating disturbance.
16.	2019/04	Postherpetic hypohidrosis-related isotopic response associated with lichen planus and lichen amyloidosis.
17.	2019/02	A Case of interstitial pneumonia during ustekinumab treatment in a patient with psoriatic arthritis
18.	2013/04	YKL-40 is a serum biomarker reflecting the severity of cutaneous lesions in psoriatic arthritis.
19.	2012/11	Eccrine poromatosis associated with polychemotherapy.
20.	2011/12	Granulysin-producing cytotoxic T cells in the mucocutaneous lesions of Behcet disease: a distinct inflammatory response from erythema nodosum.
21.	2011/10	YKL-40 (chitinase 3-like-1) as a biomarker for psoriasis vulgaris and pustular psoriasis.
22.	2011/05	Markedly elevated serum levels of calcium-binding S100A8/A9 proteins in psoriatic arthritis are due to activated monocytes/macrophages.
23.	2007/12	A novel homozygous mutation of the EVER1/TMC6 gene in a Japanese patient with epidermodysplasia verruciformis.
Display 5 items
Display all(23)

■ Presentation

1.	2023/05/11	The predictive and diagnostic biomarkers of immune-related adverse events vary by the affected organ （Poster notice，General）
2.	2022/12/02	Cytokine profiles for predicting the development of COVID-19 vaccine-associated bullous pemphigoid （Speech，General）
3.	2021/12/03	Occurrence of immune reconstitution inflammatory syndrome can be predicted by cytokine profiles in dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid （Speech，General）
4.	2020/12/11	Neutrophil-to-lymphocyte ratio as a useful biomarker can predict outcomes in dipeptidyl peptidase-4 inhibitor associated bullous pemphigoid （Poster notice，General）